

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Modern Chinese Medicine Group Co., Ltd.

現代中藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1643)

HIGH CONCENTRATION OF SHAREHOLDING

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in respect of the concentration of the shareholding of Modern Chinese Medicine Group Co., Ltd. (the “**Company**”) in the hands of a limited number of shareholders of the Company (the “**Shareholders**”) as at 30 March 2026.

HIGH CONCENTRATION OF SHAREHOLDING

The Company noted that an announcement has been published by the Securities and Futures Commission (the “**SFC**”) on 14 April 2026 (the “**SFC Announcement**”).

As disclosed in the SFC Announcement, the SFC has recently completed an enquiry into the shareholding of the Company. The SFC findings suggested that, as at 30 March 2026, 25 shareholders and their related parties held an aggregate of 652,325,282 shares of the Company (the “**Shares**”), representing 90.6% of the issued Shares. As such, only 67,674,718 Shares (representing 9.4% of the issued Shares) were in the hands of other Shareholders.

Based on the SFC Announcement, as at 30 March 2026, the shareholding structure of the Company was as follows:

	Number of Shares held (Shares)	% of total number of issued Shares (%)
25 Shareholders and their related parties	652,325,282	90.6
Other Shareholders	<u>67,674,718</u>	<u>9.4</u>
Total	<u><u>720,000,000</u></u>	<u><u>100.0</u></u>

As stated in the SFC Announcement,

- (a) the closing price of the Shares rose 316% from HK\$0.51 on 31 December 2025 to HK\$2.12 on 30 March 2026; and
- (b) on 13 April 2026, the price of the Shares closed at HK\$2.94, representing an increase of 476% from the closing price of HK\$0.51 on 31 December 2025.

The board (the “**Board**”) of the directors (the “**Directors**”) of the Company wishes to clarify that the information above is extracted from the SFC Announcement and the Company has not independently verified such information other than the information set out in paragraphs (a) to (b) above. Please refer to the SFC Announcement for more information.

PUBLIC FLOAT

Based on the information available and to the Directors’ best knowledge after making all reasonable enquiries, the Company confirms that not less than 25% of the Company’s issued Shares are in the hands of the public as at 30 March 2026 and as at the date of this announcement, the Company is able to comply with the public float requirement under the Rules Governing the Listing of Securities of the Stock Exchange.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares. Further, as a result of the high concentration of shareholding, the Company’s securities may not have a genuine market or its shareholding may have been concentrated in the hands of a few Shareholders.

By Order of the Board
Modern Chinese Medicine Group Co., Ltd.
Zhang Hongli
Executive Director

Hong Kong, 14 April 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Ms. Sun Xinlei, Ms. Zhang Hongli and Ms. Jia Yanru; and three independent non-executive Directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.